首页> 美国卫生研究院文献>Frontiers in Immunology >Biomarker Tools to Design Clinical Vaccines Determined from a Study of Annual Listeriosis Incidence in Northern Spain
【2h】

Biomarker Tools to Design Clinical Vaccines Determined from a Study of Annual Listeriosis Incidence in Northern Spain

机译:根据西班牙北部年度李斯特菌病发病率研究确定的设计临床疫苗的生物标志物工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Two regions of northern Spain, Gipuzkoa, and Cantabria present high annual incidence of listeriosis (1.86 and 1.71 cases per 100,000 inhabitants, respectively). We report that the high annual incidences are a consequence of infection with highly virulent Listeria monocytogenes isolates linked to fatal outcomes in elderly patients with cancer. In addition, listeriosis patients with cancer present low IL-17A/IL-6 ratios and significantly reduced levels of anti-GAPDH1–22 antibodies, identified as two novel biomarkers of poor prognosis. Analysis of these biomarkers may aid in reducing the incidence of listeriosis. Moreover, GAPDH1–22-activated monocyte-derived dendritic cells of listeriosis patients with cancer seem useful tools to prepare clinical vaccines as they produce mainly Th1 cytokines.
机译:西班牙北部的两个地区吉普斯夸(Gipuzkoa)和坎塔布里亚(Cantabria)的李斯特菌病年发病率很高(分别为每10万居民1.86和1.71例)。我们报道,每年的高发病率是感染高致病力单核细胞增生性李斯特菌分离株的结果,而这些分离株与老年癌症患者的致命结局有关。此外,患有癌症的李斯特菌病患者的IL-17A / IL-6比率低,抗GAPDH1-222抗体的水平显着降低,这被认为是预后不良的两个新的生物标志物。对这些生物标志物的分析可能有助于减少李斯特菌病的发生。此外,患有癌症的李斯特菌病患者的GAPDH1–22激活的单核细胞衍生树突状细胞似乎是制备临床疫苗的有用工具,因为它们主要产生Th1细胞因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号